Cisplatin resistance and DNA repair

Cancer Treatment Reviews

Volumn 23, Issue 5-6, 1997, Pages 341-366

  Crul, M ^a   Schellens, J H M ^a   Beijnen, J H ^b   Maliepaard, M ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b SLOTERVAART HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; PROTEIN P53;

APOPTOSIS; ARTICLE; BASE MISPAIRING; CELL CYCLE; DNA ADDUCT; DNA REPAIR; DRUG DNA BINDING; DRUG RESISTANCE; EXCISION REPAIR; HUMAN; HUMAN CELL;

EID: 0031443744     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0305-7372(97)90032-3     Document Type: Article

References (128)

1. Loehrer, S. & Einhorn, A. D. J. (1984) Diagnosis and treatment: drugs five years later: Cisplatin. Ann. Int. Med. 100: 704-713.
2. Chu, G. (1994) Cellular responses to cisplatin. The roles of DNA-binding proteins and DNA repair. J. Biol. Chem. 269: 787-790.
3. Roberts, J. M., Knox R. J., Friedlos F. & Lydall D. A. (1986) DNA as the target for the cytotoxic and anti-tumour action of platinum coordination complexes: comparative in vitro and in vivo studies of cisplatin and carboplatin. In: McBrien, D. C. H. & Slater, T. F. eds, Biochemical Mechanisms of Platinum Antitumour Drugs. Oxford: IRL Press, p. 29.
4. Eastman, A. (1987) The formation, isolation and characterization of DNA adducts produced by anticancer platinum complexes. Pharmacol. Ther. 34: 155-166.
5. Eastman, A. (1990) Activation of programmed cell death by anticancer agents: cisplatin as a model system. Cancer Cells 2: 275-280.
6. Ma J. (1996) Clinical and Preclinical Pharmacokinetic and Dynamic Studies with Cisplatin, Topocetan and Docetaxel. Thesis Erasmus University Rotterdam, The Netherlands.
7. Anthoney, D. A., Mclllwrath A. J., Gallagher W. M., Edlin A. R. M. & Brown R. (1996) Microsatellite instability, apoptosis and loss of p53 function in drug-resistant tumor cells. Cancer Res 56: 1374-1381.
8. Sorenson, C. M. & Eastman A. (1988) Mechanism of cis-diamminedichloroplatinum(II)-induced cytotoxicity: role of G2 arrest and DNA double-strand breaks. Cancer Res 48: 4484-4488.
9. 2 phase and cell death induced by cisplatin. J. Natl. Cancer Inst. 82: 749-755.
10. Andrews, P. A. & Howell, S. B. (1990) Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells 2: 35-43.
11. Hill, B. T. (1996) Drug resistance: An overview of the current state of the art. Int. J. Oncol 9: 197-203.
12. Timmer-Bosscha, H., Mulder, N. H. & de Vries, E. G. (1992) Modulation of cisdiamminedichloroplatinum(II) resistance: a review. Br. J. Cancer 66: 227-238.
13. Zamble, D. B. & Lippard, S. J. (1995) Cisplatin and DNA repair in cancer chemotherapy. Trends Biochem. Sci. 20: 435-439.
14. Johnson, S.W., Perez R. P., Godwin, A. K. et al. (1994) Role of platinum-DNA adduct formation and removal in cisplatin resistance in human ovarian cancer cell lines. Biochem. Pharmacol. 47: 689-697.
15. Salles B., Frit, P., Provot, C., Jaeg, J. P. & Calsou P. (1995) In vitro eukaryotic DNA excision repair assays: An overview. Biochimie 77: 796-802.
16. van Vuuren, A. J. (1995) Nucleotide Excision Repair: ERCC1 and TFIIH Complexes. Thesis Erasmus University Rotterdam, The Netherlands.
17. Wood, R. D. (1996) DNA repair in eurkaryotes. Ann. Rev. Biochem. 65: 135-167.
18. Sancar, A. (1995) DNA repair in humans. Ann. Rev. Genet. 29: 69-105.
19. Sobol R. W., Horton J. K., Kühn R. et al. (1996) Requirement of mammalian DNA polymerase-b in base-excision repair. Nature, 379: 183-186.
20. Mu, D., Hsu, D. S. & Sancar A. (1996) Reaction mechanism of human DNA repair excision nuclease. J. Biol. Chem. 271: 8285-8294.
21. Sancar, A. (1996) DNA excision repair. Ann. Rev. Biochem. 65: 43-81.
22. Friedberg, E. C. (1996) Relationships between DNA repair and transcription. Ann. Rev. Biochem. 65: 15-42.
23. Hanawalt, P. C. (1994) Transcription-coupled repair and human disease. Science 266: 1957-1958.
24. Kaufmann, W. K. (1989) Pathway of human cell post-replication repair. Carcinogenesis 10: 1-11.
25. Kunkel, T. A. (1995) DNA-mismatch repair - The intracacies of eukaryotic spell-checking. Curr. Biol. 5: 1091-1094.
26. Wang, Z., Wu, X. & Friedberg, E. C. (1992) Excision repair of DNA in nuclear extracts from the yeast Saccharomyces cerevisiae. Biochemistry 31: 3694-3702.
27. Aebi, S., Kurdihaidar B., Gordon, R. et al. (1996) Loan of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res. 56: 3087-3090.
28. O'Donovan,A. & Wood, R. D. (1993) Identical defects in DNA repair in xeroderma pigmentosum group G and rodent ERCC group 5. Nature 363: 185-188.
29. Hoeijmakers, J. H. & Bootsma, D. (1994) DNA repair. Incisions for excision. Nature 371: 654-655.
30. Doetsch, P. W. (1995) What's old is new: An alternative DNA excision repair pathway. Trends Biochem. Sci. 20: 384-386.
31. Freyer, G. A., Davey, S., Ferrer, J. V., Martin, A. M., Beach, D. & Doetsch P. W. (1995) An alternative eukaryotic DNA excision repair pathway. Mol. Cell. Biol. 15: 4572-4577.
32. Calsou, P. & Salles B. (1993) Role of DNA repair in the mechanisms of cell resistance to alkylating agents and cisplatin. Cancer Chemother. Pharmacol. 32: 85-89.
33. Estman, A. & Schulte, N. (1988) Enhanced DNA repair as a mechanism of resistance to cisdiamminedichloroplatinum(II). Biochemistry 27: 4730-4734.
34. Sekiya, S., Oosaki, T., Andoh, S., Suzuki, N., Akaboshi, M. & Takamizawa, H. (1989) Mechanisms of resistance to cis-diamminedichloroplatinum (II) in a rat ovarian carcinoma cell linee. Eur. J. Cancer Clin. Oncol. 25: 429-437.
35. Sheibani, N., Jennerwein M. M. & Eastman, A. (1989) DNA repair in cells sensitive and resistant to cis-diamminedichloroplatinum(II): host cell reactivation of damaged plasmid DNA. Biochemistry 28: 3120-3124.
36. Vilpo, J. A., Vilpo, L. M. Szymkowski, D. E., O'Donovan, A. & Wood, R. D. (1995) An XPG DNA repair defect causing mutagen hypersensitivity in mouse leukemia L1210 cells D. Mol. Cell Biol. 15: 290-297.
37. Ali-Osmon, F., Berger, M. S. Rairkar, A. & Stein, D. E. (1994) Enhanced repair of a cisplatin-damaged reporter chloramphenicol-O- acetyltransferase gene and altered activities of DNA polymerases alpha and beta, and DNA ligase in cells of a human malignant glioma following in vivo cisplatin therapy. J. Cell Biochem. 54: 11-19.
38. Bedford, P., Fichtinger-Schepman, A. M. J., Shellard, S. A., Walker, M. C., Masters, J. R. W. & Hill, B. T. (1988) Differential repair of platinum-DNA adducts in human bladder and testicular tumor continuous cell lines. Cancer Res 48: 3019-3024.
39. Lai, G. M., Ozols, R. F., Smyth, J. F., Young, R. C. & Hamilton, T. C. (1988) Enhanced DNA repair and resistance to cisplatin in human ovarian cancer. Biochem. Pharmacol. 37: 4597-4600.
40. Masuda, H., Tanaka, T., Matsuda, H. & Kusaba, I. (1990) Increased removal of DNA-bound platinum in a human ovarian cancer cell line resistant to cis-diamminedichloroplatinum(II). Cancer Res. 50: 1863-1866.
41. Parker, R. J., Eastman, A., Bostick-Bruton, F. & Reed, E. (1991) Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation. J. Clin. Invest. 87: 772-777.
42. Hill, B. T., Shellard, S. A., Hosking, L. K., Fichtinger-Schepman, A. M. & Bedford, P. (1990) Enhanced DNA repair and tolerance of DNA damage associated with resistance to cis-diammine-dichloroplatinum (II) after in vitro exposure of a human teratoma cell line to fractionated X-irradiation. Int. J. Rad. Oncol. Biol. Phys. 19: 75-83.
43. Jones, S. L., Hickson, I. D., Harris, A. L. & Harnett, P. R. (1994) Repair of cisplatin-DNA adducts by protein extracts from human ovarian carcinoma. Int. J. Cancer 59: 388-393.
44. Szymkowski, D. E., Yarema, K., Essigmann, J. M., Lippard, S. J. & Wood, R. D. (1992) An intrastrand d(GpG) platinum crosslink in duplex M13 DNA is refractory to repair by human cell extracts. Proc. Natl. Acad. Sci. U.S.A. 89: 10772-10776.
45. Huang, J. C., Zamble, D. B., Reardon, J. T., Lippard, S. J. & Sancar, A. (1994) HMG-domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision nuclease. Proc. Natl. Acad. Sci. U.S.A. 91: 10394-10398.
46. Calsou P., Frit, P. & Salles, B. (1992) Repair synthesis by human cell extracts in cisplatin-damaged DNA is preferentially determined by minor adducts. Nucleic Acids Res. 20: 6363-6368.
47. Bungo, M., Fujiwara, Y., Kasahara, K. et al. (1990) Decreased accumulation as a mechanism of resistance to cis-diamminedichloroplatinum(II) in human non-small cell lung cancer cell lines: relation to DNA damage and repair. Cancer Res. 50: 2549-2553.
48. Zeller, W. J., Fruhauf, S., Chen, G., Keppler, B. K., Frei, E. & Kaufmann, M. (1991) Chemoresistance in rat ovarian tumours. Eur. J. Cancer 27: 62-67.
49. Jones, J. C., Zhen, W., Reed, E., Parker, R. J., Sancer, A. & Bohr, V. A. (1991) Gene-specific formation and repair of cisplatin intrastrand adducts and interstrand cross-links in Chinese hamster ovary cells. J. Biol. Chem. 266: 7101-7107.
50. Zhen, W., Link, C. J., Jr, O'Connor, P. M. et al. (1992) Increased gene-specific repair of cisplatin interstrand cross-links in cisplatin-resistant human ovarian cancer cell lines. Mol. Cell. Biol. 12: 3689-3698.
51. Visse, R. (1994) DNA Repair by the Escherichia Coli UvrABC Endonuclease. Thesis University of Leiden, The Netherlands.
52. Chu, G. & Chang, E. (1990) Cisplatin-resistant cells express increased levels of a factor that recognizes damaged DNA. Proc. Natl. Acad. Sci. U.S.A. 87: 3324-3328.
53. Shivji, K. K., Kenny, M. K. & Wood, R. D. (1992) Proliferating cell nuclear antigen is required for DNA excision repair. Cell 69: 367-374.
54. Dabholkar, M., Vionnet, J., Bostick-Bruton, F., Yu, J. J. & Reed, E. (1994) Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum chemotherapy. J. Clin. Invest. 94: 703-708.
55. Bissett, D., McLaughlin, K., Kelland, L R. & Brown, R. (1993) Cisplatin-DNA damage recognition proteins in human tumour extracts. Br. J. Cancer 67: 742-748.
56. Clugston, C. K., Kenny, M. K. & Brown, R. (1992) Binding of human single-stranded DNA binding protein to DNA damaged by the anticancer drug cis-diamminedichloroplatinum (II). Cancer Res. 52: 6375-6379.
57. Chao, C. C., Huang, S. L., Huang H. M. & Lin-Chao, S. (1991) Cross-resistance to UV radiation of a cisplatin human cell line: overexpression of cellular factors that recognize UV-modified DNA. Mol. Cell Biol. 11: 2075-2080.
58. Chao, C. C., Huang, S. L., Lee, L Y. & Lin-Chao, S. (1991) Identification of inducible damage-recognition proteins that are overexpressed in HeLa cells resistant to cis-diamminedichloroplatinum (II). Biochem. 277: 875-878.
59. Dabholkar, M., Bostick-Bruton, F., Weber, C., Bohr, V. A., Egwuagu, C. & Reed, E. (1992) ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients. J. Natl. Cancer Inst. 84: 1512-1517.
60. Taverna, P., Hansson, J., Scanlon, K. J. & Hill, B. T. (1994) Gene expression in X-irradiated human tumour cell lines expressing cisplatin resistance and altered DNA repair capacity. Carcinogenesis 15: 2053-2056.
61. Bohr, V. A. (1991) Gene specific DNA repair. Carcinogenesis 12: 1983-1992.
62. McLaughlin, K., Coren, G., Masters, J. & Brown, R. (1993) Binding activities of cis-platin-damage-recognition proteins in human tumour cell lines. Int. J. Cancer, 53: 662-666.
63. Drapkin, R., Reardon, J. T., Ansari, A. et al. (1994) Dual role of TFIIH in DNA excision repair and in transcription by RNA polymerase II. Nature 368: 769-772.
64. Haldar, S., Negrini, M., Monne, M., Sabbioni, S. & Croce, C. M. (1994) Down-regulation of bcl-2 by p53 in breast cancer cells. Cancer Res. 54: 2095-2097.
65. Sullivan, D. T. (1995) DNA excision repair and transcription: Implications for genome evolution. Curr. Opinion Gen. Dev. 5: 786-791.
66. May, A., Nairn, R. S., Okumoto, D. S. et al. (1993) Repair of individual DNA strands in the hamster dihydrofolate reductase gene after treatment with ultraviolet light, alkylating agents, and cisplatin. J. Biol. Chem. 268: 1650-1657.
67. Modrich, P. (1994) Mismatch repair, genetic stability, and cancer. Science, 266: 1959-1960.
68. Chung, D. C. & Rustgi, A. K. (1995) DNA mismatch repair and cancer. Gastroenterology 109: 1685-1699.
69. Kolodner, R. (1996) Biochemistry and genetics of eukaryotic mismatch repair. Gene Develop. 10: 1433-1442.
70. Duckett, D. R., Drummond, J. T., Murchie, A. I. et al. (1996) Human MutSalpha recognizes damaged DNA base pairs containing O6-methylguanine, O4-methylthymine, or the cisplatin-d(GpG) adduct. Proc. Natl. Acad. Sci. U.S.A. 93: 6443-6447.
71. Mellon, I. & Champe, G. N. (1996) Products of DNA mismatch repair genes mutS and mutL are required for transcription-coupled nucleotide-excision repair of the lactose operon in Escherichia coli. Proc. Natl. Acad. Sci. U.S.A. 93: 1292-1297.
72. Mol, M. A., van der Schans, G. P. & Lohman, P. H. (1993) Quantification of sulfur mustard-induced DNA interstrand cross-links and single-strand breaks in cultured human epidermal keratinocytes. Mutat. Res. 294: 235-245.
73. 2 cell cycle checkpoint. Cancer Res. 55: 3721-3725.
74. Branch, P., Aquilina, G., Bignami M. & Karran, P. (1993) Defective mismatch binding and a mutant phenotype in cells tolerant to DNA damage. Nature 362: 652-654.
75. Fink, D., Nebel, S., Aebi, S. et al. The role of DNA mismatch repair in platinum drug resistance. Cancer Res. 56: 4881-4886.
76. Anthony, A. & Brown, R. (1995) The detection of genomic instability in drug resistant human tumour cell lines. Proc. Am. Ass. Cancer Res. 36: 323.
77. Mello J. A., Acharya, S., Fishel, R. & Essigmann, J. M. (1996) The mismatch-repair protein hMSH2 binds selectively to DNA adducts of the anticancer drug cisplatin. Chem. Biol. 3: 579-589.
78. Mellon, I., Rajpal, D. K., Koi, M., Boland, C. R. & Champe, G. N. (1996) Transcription-coupled repair deficiency and mutations in human mismatch repair genes. Science 272: 557-560.
79. Bruhn, S. L., Pil, P. M., Essigmann, J. M., Housman, D. E. & Lippard, S. J. (1992) Isolation and characterization of human cDNA clones encoding a high mobility group box protein that recognizes structural distortions to DNA caused by binding of the anticancer agent cisplatin. Proc. Natl. Acad. Sci. U.S.A. 89: 2307-2311.
80. Donahue, B. A., Augot, M., Bellon, S. F. et al. (1990) Characterization of a DNA damage-recognition protein from mammalian cells that binds specifically to intrastrand d(GpG) and d(ApG) DNA adducts of the anticancer drug cisplatin. Biochemistry 29: 5872-5880.
81. Grosschedl, R., Giese, K. & Pagel, J. (1994) HMG domain proteins: architectural elements in the assembly of nucleoprotein structures. Trends Genet. 10: 94-100.
82. McA'Nulty M. M. & Lippard, S. J. (1995) Consequences of HMG-domain protein binding to cisplatin-modified DNA. Nucleic Acids Mol. Biol. 9: 264-284.
83. Anin, M. F. & Leng, M. (1990) Distortions induced in double-stranded oligonucleotides by the binding of cis- or trans-diammine-dichloroplatinum(II) to the d(GTG) sequence. Nucleic Acids Res. 18: 4395-4400.
84. Brown, S. J., Kellett, P. J. & Lippard, S. J. (1993) Ixr1, a yeast protein that binds to platinated DNA and confers sensitivity to cisplatin. Science 2621: 603-605.
85. McA'Nulty, M. M. & Lippard, S. J. (1996) The HMG-domain protein Ixr1 blocks excision repair of cisplatin-DNA adducts in yeast. Mutat. Res. -DNA Repair 362: 75-86.
86. Billings, P. C., Engelsberg, B. N. & Hughes, E. N. (1994) Proteins Binding to Cisplatin-Damaged DNA in Human Cell Lines. Cancer Invest. 12: 597.
87. Hughes E. N., Engelsberg, B. N. & Billings, P. C. (1992) Purification of nuclear proteins that bind to cisplatin-damaged DNA. Identity with high mobility group proteins 1 and 2. J. Biol. Chem. 267: 13520-13527.
88. Marples, B., Adomat, H., Billings, P. C., Farrell, N. P., Koch, C. J. & Skov, K. A. (1994) Recognition of platinum-induced DNA damage by nuclear proteins: screening for mechanisms. Anti-Cancer Drug Des. 9: 389-399.
89. Pil, P. M. & Lippard, S. J. (1992) Specific binding of chromosomal protein HMG1 to DNA damaged by the anticancer drug cisplatin. Science, 256: 234-237.
90. Toney, J. H., Donahue, B. A., Kellett, P. J., Bruhn, S. L., Essigmann, J. M. & Lippard, S. J. (1989) Isolation of cDNAs encoding a human protein that binds selectively to DNA modified by the anticancer drug cis-diamminedichloroplatinum. Proc. Natl. Acad. Sci. U.S.A. 86:8328-8332.
91. Isackson, P. J., Fishback, J. L., Bidney, D. L. & Reeck, G. R. (1979) Preferential affinity of high molecular weight high mobility group non- histone chromatin proteins for single-stranded DNA. J. Biol. Chem. 254: 5569-5572.
92. Boulikas, T. (1996) DNA lesion-recognizing proteins and the p53 connection. Anticancer Res. 16: 225-242.
93. Kane S. A. & Lippard, S. J. (1996) Photoreactivity of platinum(II) in cisplatin-modified DNA affords specific cross-links to HMG domain proteins. Biochemistry 35: 2180-2188.
94. Enoch, T. & Norbury, C. (1995) Cellular responses to DNA damage: cell-cycle checkpoints, apoptosis and the roles of p53 and ATM. Trends Biochem. Sci. 20: 426-430.
95. Brown R. (1995) Mechanisms of cisplatin resistance: a post-DNA-damage perspective. FORUM Trends Exp. Clin. Med. 5: 263-274.
96. Gibbons, G. R., Kaufmann, W. K. & Chaney, S. G. (1991) Role of DNA replication in carrier-ligand-specific resistance to platinum compounds in L1210 cells. Carcinogenesis 12: 2253-2257.
97. Mamenta, E. L., Poma, E. E., Kaufmann, W. K., Delmastro, D. A., Grady, H. L. & Chaney, S. G. (1994) Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines. Cancer Res. 54: 3500-3505.
98. Hoffmann, J. S., Pillaire, M. J., Maga, G., Podust, V., Hubscher, U. & Villani, G. (1995) DNA polymerase beta bypasses in vitro a single d(GpG)-cisplatin adduct placed on codon 13 of the HRAS gene. Proc. Natl. Acad. Sci. U.S.A. 92: 5356-5360.
99. Fornace, A. J., Jr., Zmudzka, B., Hollander, M. C. & Wilson, S. H. (1989) Induction of beta-polymerase mRNA by DNA-damaging agents in Chinese hamster ovary cells. Mol. Cell Biol. 9: 851-853.
100. Evans, D. L. & Dive, C. (1993) Effects of cisplatin on the induction of apoptosis in proliferating hepatoma cells and nonproliferating immature thymocytes. Cancer Res. 53: 2133-2139.
101. Fan, S., El-Deiry, W. S., Bae, I. et al. (1994) p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res. 54: 5824-5830.
102. Thiebaut, F., Enns, R. & Howell, S. B. (1994) Cisplatin sensitivity correlates with its ability to cause cell cycle arrest via a wee1 kinase-dependent pathway in Schizosaccharomyces pombe. J. Cell Physiol 159: 506-514.
103. Perego, P., Girola, M., Righetti, S. C. et al. (1996) Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res. 56: 556-562.
104. Ormerod, M. G., Orr, R. M. & Peacock, J. H. (1994) The role of apoptosis in cell killing by cisplatin: a flow cytometric study. Br. J. Cancer 69: 93-100.
105. Vogelstein, B. & Kinzler, K. W. (1992) p53 function and dysfunction. Cell 70: 523-526.
106. Fritsche, M., Haessler, C. & Brandner, G. (1993) Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents. Oncogene 8: 307-318.
107. Miyashita T. & Reed, J. C. (1995) Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80: 292-299.
108. Zhan Q., Carrier, F. & Fornace, A. J., Jr. (1993) Induction of cellular p53 activity by DNA-damaging agents and growth arrest. Mol. Cell Biol. 13: 4242-4250.
109. Hollander, M. C., Alamo, I., Jackman, J., Wang, M. G., McBride, O. W. & Fornace, A. J., Jr. (1993) Analysis of the mammalian gadd45 gene and its response to DNA damage. J. Biol. Chem. 268: 24385-24393.
110. Eliopoulos, A. G., Kerr, D. J., Herod, J. et al. (1995) The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2. Oncogens 11: 1217-1228.
111. Fajac, A., Dasilva, J., Ahomadegbe, J. C. et al. (1996) Cisplatin-induced apoptosis and p53 gene status in a cisplatin-resistant human ovarian carcinoma cell line. Int. J. Cancer 68: 67-74.
112. Kondo, S., Barnett, G. H., Hara, H., Morimura, T. & Takeuchi, J. (1995) MDM2 protein confers the resistance of a human glioblastoma cell line to cisplatin-induced apoptosis. Oncogene 10: 2001-2006.
113. Butz, K., Shahabeddin, L., Geisen, C., Spitkovsky, D., Ullmann, A. & Hoppe-Seyler, F. (1995) Functional p53 protein in human papillomavirus-positive cancer cells. Oncogene 10: 927-936.
114. Lowe, S. W., Bodis, S., McClatchey, A. et al. (1994) p53 status and the efficacy of cancer therapy in vivo. Science 266: 807-810.
115. Brown, R., Clugston, C., Burns, P. et al. (1993) Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines. Int. J. Cancer 55: 678-684.
116. Fan, S., Smith, M. L., Rivet, D. J. et al. (1995) Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentotoxifylline. Cancer Res. 55: 1649-1654.
117. Herod, J. J., Eliopoulos, A. G., Warwick, J., Niedobitek, G., Young, L. S. & Kerr, D. J. (1996) The prognostic significance of Bcl-2 and p53 expression in ovarian carcinoma. Cancer Res. 56: 2178-2184.
118. Fujiwara, T., Grimm, E. A., Mukhopadhyay, T., Zhang, W. W., Owen-Schaub, L. B. & Roth, J. A. (1994) Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res. 54: 2287-2291.
119. Gjerset, R. A., Turla, S. T., Sobol, R. E. et al. (1995) Use of wild-type p53 to achieve complete treatment sensitization of tumor cells expressing endogenous mutant p53. Mol. Carcinog. 14: 275-285.
120. Kondo, S., Barna, B. P., Morimura, T. et al. (1995) Interleukin-1 beta-converting enzyme mediates cisplatin-induced apoptosis in malignant glioma cells. Cancer Res. 55: 6166-6171.
121. Davol P. A., Goulette, F. A., Frackelton, A. R. & Darnowski, J. W. (1996) Modulation of p53 expression by human recombinant interferon-alpha 2a correlates with abrogation of cisplatin resistance in a human melanoma cell line. Cancer Res. 56: 2522-2526.
122. Dutta, A., Ruppert, J. M., Aster, J. C. & Winchester, E. (1993) Inhibition of DNA replication factor RPA by p53. Nature 365: 79-82.
123. Li, R. & Botchan, M. R. (1993) The acidic transcriptional activation domains of VP16 and p53 bind the cellular replication protein A and stimulate in vitro BPV-1 DNA replication. Cell 73: 1207-1221.
124. Wyllie, A. H. (1993) Apoptosis (the 1992 Frank Rose Memorial Lecture). Br. J. Cancer, 67: 205-208.
125. Havrilesky, L. J., Elbendary, A., Hurteau, J. A., Whitaker, R. S., Rodriguez, G. C. & Berchuck, A. (1995) Chemotherapy-induced apoptosis in epithelial ovarian cancers. Obstet. Gynecol. 85: 1007-1010.
126. Otto, A. M., Paddenberg, R., Schubert, S. & Mannherz, H. G. (1996) Cell-cycle arrest, micronucleus formation, and cell death in growth inhibition of MCF-7 breast cancer cells by tamoxifen and cisplatin. J. Cancer Res. Clin. Oncol. 122: 603-512.
127. Ormerod, M. G., O'Neill, C., Robertson, D., Kelland, L. R. & Harrap, K. R. (1996) cis-diamminedichloroplatinum(II) induced cell death through apoptosis in sensitive and resistant human ovarian carcinoma cell lines. Cancer Chemother. Pharmacol. 37: 463-471.
128. Borner, M. M., Myers, C. E., Sartor, O. et al. (1995) Drug-induced apoptosis is not necessarily dependent on macromolecular synthesis or proliferation in the p53-negative human prostate cancer cell line PC-3. Cancer Res. 55: 2122-2128.